Hudson Bay Capital Management LP Buys 321,631 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Hudson Bay Capital Management LP raised its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 60.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 849,873 shares of the company's stock after acquiring an additional 321,631 shares during the quarter. Hudson Bay Capital Management LP owned about 0.62% of Vir Biotechnology worth $6,238,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of VIR. Barclays PLC grew its position in shares of Vir Biotechnology by 1.3% during the 3rd quarter. Barclays PLC now owns 550,186 shares of the company's stock worth $4,121,000 after purchasing an additional 7,287 shares in the last quarter. KBC Group NV grew its position in shares of Vir Biotechnology by 136.5% during the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after purchasing an additional 5,177 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Vir Biotechnology by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 29,202 shares of the company's stock worth $214,000 after purchasing an additional 2,922 shares in the last quarter. abrdn plc acquired a new position in shares of Vir Biotechnology during the 4th quarter worth approximately $2,666,000. Finally, State of Alaska Department of Revenue grew its position in shares of Vir Biotechnology by 33.0% during the 4th quarter. State of Alaska Department of Revenue now owns 202,441 shares of the company's stock worth $1,485,000 after purchasing an additional 50,199 shares in the last quarter. 65.32% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on VIR. The Goldman Sachs Group decreased their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Needham & Company LLC decreased their target price on shares of Vir Biotechnology from $19.00 to $14.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. HC Wainwright restated a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. Finally, Barclays increased their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $32.86.

Vir Biotechnology Stock Performance

Shares of NASDAQ VIR traded up $0.05 during trading hours on Friday, hitting $4.60. 1,307,211 shares of the stock were exchanged, compared to its average volume of 1,373,404. The company has a market cap of $635.89 million, a PE ratio of -1.17 and a beta of 1.36. The company's fifty day simple moving average is $5.97 and its two-hundred day simple moving average is $7.84. Vir Biotechnology, Inc. has a 1-year low of $4.32 and a 1-year high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $8.59 million. During the same quarter in the prior year, the business posted ($0.48) EPS. The business's revenue was down 94.6% on a year-over-year basis. As a group, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares in the company, valued at $6,948,373.95. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Verneuil Vanina De sold 7,373 shares of the firm's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the sale, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. This represents a 8.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,049 shares of company stock worth $649,232 over the last quarter. Corporate insiders own 15.60% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).